A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of VSA012 After Single Ascending Doses in Healthy Volunteers
Latest Information Update: 17 Jan 2025
Price :
$35 *
At a glance
- Drugs VSA 012 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Visirna Therapeutics
- 17 Jan 2025 New trial record